Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC (PATAGONIA)

tiistai 10. marraskuuta 2026 päivittänyt: AstraZeneca

A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-Based Combinations in Adult Participants With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA)

Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This is a Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

This study is designed as non-comparative.

Participants will be randomised to Treatment A or B.

In the module 1 of this study, Dato-DXd-based regimens will be assessed in participants with non-AGA NSCLC whose tumours have been prospectively identified as TROP2 NMR+.

The proposed primary objectives are to assess the efficacy of Dato-DXd combined with durvalumab and carboplatin and Dato-DXd combined with durvalumab in terms of PFS per RECIST 1.1 as assessed by the investigator.

Participants in both treatment groups will receive study treatment medicines until investigator-assessed radiological progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or an intervention discontinuation criterion is met. There is no maximum limit to the number of cycles of Dato-DXd and/or durvalumab that a participant in either treatment group can receive. The maximum treatment for carboplatin is 4 cycles.

The study will be conducted in several countries worldwide.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

250

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Ciudad Autonoma Buenos Aires, Argentiina, 1405
        • Research Site
      • Ciudad de Buenos Aires, Argentiina, C1427ARO
        • Research Site
      • La Rioja, Argentiina, 5300
        • Research Site
      • Rosario, Argentiina, 2000
        • Research Site
      • Rosario, Argentiina, S2000KZE
        • Research Site
      • San Juan, Argentiina, 5400
        • Research Site
      • Viedma, Argentiina, R8500ACE
        • Research Site
      • Adelaide, Australia, 5000
        • Research Site
      • Bedford Park, Australia, 5042
        • Research Site
      • Southport, Australia, 4215
        • Research Site
      • Waratah, Australia, 2298
        • Research Site
      • Woodville, Australia, 5011
        • Research Site
      • Blumenau, Brasilia, 89010-340
        • Research Site
      • Curitiba, Brasilia, 80810-050
        • Research Site
      • Ijuí, Brasilia, 98700-000
        • Research Site
      • Porto Alegre, Brasilia, 90610-000
        • Research Site
      • Porto Alegre, Brasilia, 91350200
        • Research Site
      • Rio de Janeiro, Brasilia, 22281-100
        • Research Site
      • Salvador, Brasilia, 40170-110
        • Research Site
      • Santa Maria, Brasilia, 97015-450
        • Research Site
      • São Paulo, Brasilia, 01246-000
        • Research Site
      • São Paulo, Brasilia, 01509-900
        • Research Site
      • São Paulo, Brasilia, 03102-006
        • Research Site
      • Teresina, Brasilia, 64049-200
        • Research Site
      • Vitória, Brasilia, 29043-260
        • Research Site
      • Cheongju-si, Etelä -Korea, 28644
        • Research Site
      • Jinju, Etelä -Korea, 660-702
        • Research Site
      • Seongnam-si, Etelä -Korea, 13620
        • Research Site
      • Seoul, Etelä -Korea, 5505
        • Research Site
      • Seoul, Etelä -Korea, 120-749
        • Research Site
      • Suwon, Etelä -Korea, 16247
        • Research Site
      • Lucca, Italia, 55100
        • Research Site
      • Orbassano, Italia, 10043
        • Research Site
      • Parma, Italia
        • Research Site
      • Rozzano, Italia, 20089
        • Research Site
      • Torrette, Italia, 60126
        • Research Site
      • Verona, Italia, 37126
        • Research Site
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • Research Site
    • Ontario
      • Brampton, Ontario, Kanada, L6R 3J7
        • Research Site
      • Toronto, Ontario, Kanada, M4N 3M5
        • Research Site
    • Quebec
      • Montreal, Quebec, Kanada, H3T 1M5
        • Research Site
      • Beijing, Kiina, 100730
        • Research Site
      • Beijing, Kiina, 100191
        • Research Site
      • Changchun, Kiina, 130021
        • Research Site
      • Changsha, Kiina, 410013
        • Research Site
      • Chengdu, Kiina, 610041
        • Research Site
      • Chongqing, Kiina, 400030
        • Research Site
      • Guangzhou, Kiina, 510000
        • Research Site
      • Hangzhou, Kiina, 310009
        • Research Site
      • Harbin, Kiina, 150081
        • Research Site
      • Nanchang, Kiina, 330000
        • Research Site
      • Nanning, Kiina, 530021
        • Research Site
      • Shandong, Kiina
        • Research Site
      • Shanghai, Kiina, 200032
        • Research Site
      • Shanghai, Kiina, 200030
        • Research Site
      • Tianjin, Kiina, 300051
        • Research Site
      • Wuhan, Kiina, 430022
        • Research Site
      • Yangzhou, Kiina, 225001
        • Research Site
      • Zhengzhou, Kiina, 450008
        • Research Site
      • Zhengzhou, Kiina, 450000
        • Research Site
      • Lodz, Puola, 93-338
        • Research Site
      • Lodz, Puola, 93-513
        • Research Site
      • Przemyśl, Puola, 37-700
        • Research Site
      • Warsaw, Puola, 00-124
        • Research Site
      • Marseille, Ranska, 13273
        • Research Site
      • Nice, Ranska, 06000
        • Research Site
      • Paris, Ranska, 75014
        • Research Site
      • Paris, Ranska, 75005
        • Research Site
      • Pessac, Ranska, 33604
        • Research Site
      • Villefranche-sur-Saône, Ranska, 69655
        • Research Site
      • Singapore, Singapore, 119228
        • Research Site
      • Singapore, Singapore, 308433
        • Research Site
      • Singapore, Singapore, 217562
        • Research Site
      • Singapore, Singapore, 168583
        • Research Site
    • California
      • Irvine, California, Yhdysvallat, 92618
        • Research Site
      • Oakland, California, Yhdysvallat, 94612
        • Research Site
    • Colorado
      • Golden, Colorado, Yhdysvallat, 80401
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Yhdysvallat, 06519
        • Research Site
    • Florida
      • Miami, Florida, Yhdysvallat, 33170
        • Research Site
      • Tampa, Florida, Yhdysvallat, 33612
        • Research Site
    • Georgia
      • Atlanta, Georgia, Yhdysvallat, 30318
        • Research Site
    • Illinois
      • Peoria, Illinois, Yhdysvallat, 61637
        • Research Site
    • South Carolina
      • Greer, South Carolina, Yhdysvallat, 29651
        • Research Site
      • Greer, South Carolina, Yhdysvallat, 29650
        • Research Site
    • Texas
      • Sugar Land, Texas, Yhdysvallat, 77479
        • Research Site
    • Utah
      • Salt Lake City, Utah, Yhdysvallat, 84112
        • Research Site
    • West Virginia
      • Morgantown, West Virginia, Yhdysvallat, 26506
        • Research Site

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

INCLUSION CRITERIA:

  1. Participant must be ≥ 18 years of age at the time of signing the ICF.

  2. Pathologically documented NSCLC that:

    1. Has documented non-squamous histology
    2. Is TROP2 NMR positive
    3. Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue.
  3. Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition.

  4. The ECOG PS of 0 to 2.

  5. Known tumour PD-L1 status.

  6. Minimum life expectancy of 12 weeks.

  7. Provision of acceptable FFPE tumour sample from a lesion not previously irradiated.

  8. At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.

  9. Adequate bone marrow reserve and organ function.

  10. Contraceptive use by participants or participant partners.

  11. Capable of giving signed informed consent.

  12. Provision of signed and dated optional informed consent.

EXCLUSION CRITERIA:

  1. As judged by the investigator, any evidence of diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.

  2. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, lentigo maligna that has undergone potentially curative therapy, or adequately treated in situ disease without evidence of disease.

  3. Squamous histology or mixed SCLC and NSCLC, or sarcomatoid variant of NSCLC, or lung neuroendocrine tumours .

  4. Has documented tumour genomic alterations in EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET exon 14, or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies.

    Note: Participants whose tumours harbour KRAS mutations are eligible for the study

  5. Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia or vitiligo, not yet improved to Grade ≤ 1 or baseline.

  6. Active or prior documented autoimmune, connective tissue or inflammatory disorders, autoimmune pneumonitis, or autoimmune myocarditis.

  7. Spinal cord compression or CNS metastases, unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 7 days prior to randomisation.

  8. History of leptomeningeal carcinomatosis or metastasis.

  9. Clinically significant corneal disease.

  10. Has active or uncontrolled HBV or HCV infection.

  11. Known HIV infection that is not well controlled.

  12. Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections.

  13. Known to have active tuberculosis infection.

  14. Mean resting QTcF > 470 ms, regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.

  15. Uncontrolled or significant cardiac disease.

  16. History of ILD/pneumonitis.

  17. Has clinically severe pulmonary function compromised.

  18. Prior exposure to:

    1. Any agent, including ADC, containing a chemotherapeutic agent targeting topoisomerase I
    2. Chemotherapy or any other systemic therapy for first-line Stage IIIB, IIIC, or IV NSCLC
    3. TROP2-targeted therapy
    4. Chloroquine/hydroxychloroquine without an adequate treatment washout period.
  19. Participants who have received any prior adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to III) are eligible, provided they meet the protocol-defined conditions.

  20. Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention.

  21. Any concurrent anti-cancer treatment.

  22. Any concomitant medication known to be associated with Torsades de Pointes.

  23. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.

  24. Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received palliative radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.

  25. Major surgical procedure or significant traumatic injury within ≤ 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.

  26. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation or concurrent participation in another clinical study.

  27. Participants with a known history of severe hypersensitivity reactions to study intervention or any excipients of these products.

  28. Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies.

  29. Allocation to a stratum that has reached the cap.

  30. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

  31. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

  32. For females only: Is pregnant (confirmed with positive serum pregnancy test), or breastfeeding, or planning to become pregnant.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Treatment A

Participants will receive Dato-DXd and durvalumab Q3W on Day 1 of every 21-day cycle.

Treatment A/B: Dato-DXd as IV infusion.

Muut nimet:
  • Datopotabab Deruxtecan

Treatment A/B: Durvalumab as IV infusion

Kokeellinen: Treatment B

Participants will receive Dato-DXd, durvalumab, and carboplatin Q3W on Day 1 of every 21-day cycle for the first 4 cycles, followed by Dato-Dxd and durvalumab Q3W

Treatment A/B: Dato-DXd as IV infusion.

Muut nimet:
  • Datopotabab Deruxtecan

Treatment A/B: Durvalumab as IV infusion

Treatment B: Carboplatin as IV infusion

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
PFS as assessed by investigator on Treatment A
Aikaikkuna: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

Primary measure of interest is the median PFS.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
PFS as assessed by investigator on Treatment B
Aikaikkuna: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

Primary measure of interest is the median PFS.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Objective Response rate (ORR) in each treatment arm
Aikaikkuna: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

ORR is defined as the proportion of participants who have a confirmed response (CR or PR), as determined by the investigator at local site per RECIST 1.1.

For each study treatment group, the primary measure of interest is the estimate of ORR.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
Duration of response (DoR) in each treatment arm
Aikaikkuna: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

DoR is defined as the time from the date of first documented confirmed response until the date of documented progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

For each study treatment group, the primary measure of interest is the median DoR.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Safety as measured by the number of patients with at least one adverse event (AE), by study treatment
Aikaikkuna: Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months

Proportion of patients with at least one AE

Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Maanantai 30. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Lauantai 16. joulukuuta 2028

Opintojen valmistuminen (Arvioitu)

Perjantai 22. joulukuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 3. syyskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 17. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 17. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • D9260C00007
  • 2025 (Yhdysvaltain NIH-apuraha/sopimus)
  • 2025-524836-21 (Rekisterin tunniste: CTIS (EU))

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

IPD-jaon aikakehys

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-jaon käyttöoikeuskriteerit

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .